IBRX Insider Trading Activity and SEC Form 4 Filings
IBRX insider trading summary
Over the past 12 months, insiders at ImmunityBio, Inc. (IBRX) reported 15 sales worth $9.3M by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $9.3M.
Latest IBRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Barry J. Simon | Director | Sell | $269K (25,000 @ $10.75) |
| Oct 2, 2026 | Cheryl Cohen | Director | Sell | $851K (81,056 @ $10.50) |
| Jul 2, 2026 | Cheryl Cohen | Director | Sell | $1.2M (131,210 @ $9.50) |
| Jul 1, 2026 | Christobel Selecky | Director | Sell | $1.4M (159,478 @ $9.02) |
| Jun 30, 2026 | Christobel Selecky | Director | Sell | $9K (1,000 @ $9.00) |
| Jun 29, 2026 | Christobel Selecky | Director | Sell | $862K (95,722 @ $9.01) |
| Jun 24, 2026 | Barry J. Simon | Director | Sell | $197K (25,000 @ $7.88) |
| Feb 24, 2026 | Barry J. Simon | Director | Sell | $901K (75,000 @ $12.01) |
| Feb 23, 2026 | Christobel Selecky | Director | Sell | $250K (25,000 @ $10.00) |
| Feb 23, 2026 | Barry J. Simon | Director | Sell | $1.7M (165,000 @ $10.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.